DAEWOONG CO., LTD.
14Patents
13Active
14Granted
50Portfolio score
Filing activity: Jun 11, 2004 → Feb 9, 2018 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7811786B1 | Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor | Chemistry; Metallurgy | 4 | Expired |
| US10117927B2 | Medium composition for preparing botulinum toxin | Chemistry; Metallurgy | 2 | Active |
| US9199965B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | Chemistry; Metallurgy | 2 | Active |
| US8409586B2 | Stable liquid formulation of human growth hormone | Human Necessities | 1 | Active |
| US9512418B2 | Method for production of botulinum toxin | Chemistry; Metallurgy | 1 | Active |
| US9926549B2 | Medium composition for preparing botulinum toxin | Chemistry; Metallurgy | 1 | Active |
| US10619143B2 | Method and producing botulinum toxin | Performing Operations; Transporting | 1 | Active |
| US11185503B2 | Stable liquid composition comprising botulinum toxin | Emerging Cross-Sectional Technologies | 0 | Active |
| US9155697B2 | Stable liquid compositions for treating stomatitis comprising epidermal growth factor | Chemistry; Metallurgy | 0 | Active |
| US9540378B2 | Composition comprising purine derivatives or salt thereof for preventing or treating atopic dermatitis | Human Necessities | 0 | Active |
| US9918937B2 | Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract | Human Necessities | 0 | Active |
| US10308923B2 | Medium composition for preparing botulinum toxin | Chemistry; Metallurgy | 0 | Active |
| US8685440B2 | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same | Human Necessities | 0 | Active |
| US10465179B2 | Medium composition for preparing botulinum toxin | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.